Jiangsu Hualan New Pharmaceutical Material (301093.SZ): The joint evaluation and approval result of the aluminum cap and formulation for pen-type injectors has been upgraded to "A" status.
Hualan Shares (301093.SZ) announced that the aluminum cap for the company's pen-type injector has recently passed the national drug supervision and administration...
Jiangsu Hualan New Pharmaceutical Material (301093.SZ) announced that the aluminum cap for the company's prefilled syringe recently passed the technical review by the Drug Evaluation Center of the National Medical Products Administration (referred to as "CDE"). It has been shown on the CDE registration information public platform for raw materials, pharmaceutical excipients, and pharmaceutical packaging materials that the status has been changed from "joint review and approval results with formulations" to "A" status.
Related Articles

Sichuan Jiuzhou Electric's subsidiary paid a total of RMB 39.8086 million in back taxes and overdue fines.

ORIENTSEC INT (08001) will have its listing status canceled starting on November 17th.

Kexing Biopharm (688136.SH) submits H-share issue application to Hong Kong Stock Exchange and publishes application materials.
Sichuan Jiuzhou Electric's subsidiary paid a total of RMB 39.8086 million in back taxes and overdue fines.

ORIENTSEC INT (08001) will have its listing status canceled starting on November 17th.

Kexing Biopharm (688136.SH) submits H-share issue application to Hong Kong Stock Exchange and publishes application materials.

RECOMMEND

SERES Faces Market Test in Hong Kong: Shares Open Below Issue Price Despite HK$220 Billion Market Valuation
06/11/2025

Copper Prices Surge While Former “Copper King” Who Outpaced Huawei and Tencent Falls into Decline
06/11/2025

National Energy Administration Reports New-Type Energy Storage Capacity Exceeds 100 Million Kilowatts by End‑September
06/11/2025


